Lixa develops revolutionary, scalable solutions for antimicrobial resistance (AMR) and the US$5T per annum biofilm problem.
Lixa has raised $1.5M in total funding. The most recent round was Series A. The last funding was announced in September 2022.
Lixa is headquartered in Perth, Australia.
Lixa develops revolutionary, scalable solutions for antimicrobial resistance (AMR) and the US$5T per annum biofilm problem.
Lixa is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lixa — Funding & Investors." VCBacked, September 6, 2022, https://www.vcbacked.co/company/lixa. Accessed August 14, 2026.
VCBacked. (2022). Lixa — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/lixa
{{cite web |title=Lixa — Funding & Investors |url=https://www.vcbacked.co/company/lixa |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated